Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
New payment models, registries and the Cross Border Healthcare Directive could help determine new ways to pay for potentially one-off treatments such as gene therapies in Europe.
The Scottish Medicines Consortium has recommended one CAR-T therapy, Novartis’ Kymriah, for use on Scotland’s National Health Service but rejected another, Gilead’s Yescarta, claiming the company has failed to prove it would be cost-effective.
Health technology appraisal institutes in England and Canada are joining forces to offer parallel scientific advice and both agencies say they are open to more international collaborations.
Health technology assessment agencies in the US, the UK and Canada are working together to develop new ways of determining value-based prices for potentially curative treatments like gene therapies.
Pressure on Vertex over access to its cystic fibrosis drug Orkambi in England is mounting after the parliamentary undersecretary for health admitted the government has already taken advice on compulsory licensing of the product.
UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.